Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2011

View Archived Issues

GABA-AT inhibitor shows promise to treat epilepsy and drug addiction

Tianjin Institute of Pharmaceutical Research discloses new agents for diabetes

Johnson & Johnson presents potential novel approach to treat diabetes and obesity

New gamma-secretase modulator shows promise in Alzheimer's disease models

Promising phase II data on NH-004 trigger additional grant from MJFF to NeuroHealing Pharmaceuticals

Apremilast completes phase II study in vulvar pain

New cannabinoid CB2 receptor agonists described

Bristol-Myers Squibb presents new chemokine CCR2 receptor modulators

Biotica claims novel sanglifehrin analogues for viral infections

British company patents novel neuropeptide Y2 receptor ligands

New monoamine reuptake inhibitors synthesized at NeuroSearch

Cleveland-based researchers to jointly launch phase I stem cell trial for MS

KemPharm and MonoSol Rx to codevelop KP-415 for ADHD

Enrollment complete in three phase III studies of TMC-435

Kuros Biosurgery completes enrollment in diabetic foot ulcer study

MorphoSys initiates dosing in MOR-202 multiple myeloma trial

DSMB recommends continuation of pivotal X-PECT study of perifosine

Tarceva approved in E.U. for specific subtype of non-small cell lung cancer

Anacor and MMV extend development agreement for malaria drug

Mitsubishi Tanabe files for approval of tenegliptin in Japan

Titan Pharmaceuticals schedules pre-NDA meeting for Probuphine

Bristol-Myers and Health Canada issue new safety information regarding Sprycel

Kissei obtains Japanese rights to DNA topoisomerase 2 inhibitor for anthracycline extravasation

Data presented from metastatic colorectal cohort of phase II trial of Delcath chemosaturation system

New approval for Cipher Pharmaceuticals' CIP-Tramadol ER

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...